Brief: Ascletis Pharma Announces Exclusive And Worldwide License Agreement Outside Greater China With Suzhou Alphamab
08/11/2021 01:36
Nov 8 (Reuters) - Ascletis Pharma Inc 1672.HK :
* A UNIT & SUZHOU ALPHAMAB CO ENTERED AN EXCLUSIVE &
WORLDWIDE
LICENSE AGREEMENT OUTSIDE GREATER CHINA FOR ASC22 (ENVAFOLIMAB)
* UNDER DEAL, ASCLETIS GOT EXCLUSIVE & WORLDWIDE LICENSE
OUTSIDE
GREATER CHINA TO DEVELOP & COMMERCIALIZE ASC22
Source text for Eikon: ID:
Further company coverage: 1672.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ascletis Pharma
See all newsFactbox: Race to launch weight-loss pill heats up as Novo wins UK approval
Brief: Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development
Factbox: Race to launch weight-loss pill heats up as Lilly wins US approval
Brief: Ascletis Pharma FY Loss Attributable Rmb359.9 Million
Brief: Ascletis Pharma Expects To Submit IND Application To U.S. FDA For ASC39 In Q3 2026